Scil Technology Completes Patient Enrollment in European Phase II Sinus Lift Study

Announced that it has successfully achieved target patient enrollment in a European Phase II clinical trial of its novel bone augmentation product, MD05, developed for bone regeneration in dental implantology.

MARTINSRIED, Germany | Jan 24, 2007 |
Scil Technology GmbH today announced that it has successfully achieved target patient enrollment in a European Phase II clinical trial of its novel bone augmentation product, MD05, developed for bone regeneration in dental implantology.

MD05 is a granular synthetic bone substitute, which is comprised of the synthetic carrier, beta-tricalcium phosphate coated with recombinant human growth and differentiation factor-5. It has been developed to combine both osteoinductive and osteoconductive properties to accelerate new bone formation and to shorten time for implant insertion after maxillary sinus floor augmentation (sinus lift surgery).

Dr. Weishui Weiser, Managing Director of Scil Technology commented:
“Achieving patient enrollment is a very important step for Scil Technology. With this achievement, Scil Technology has transitioned itself into a clinical stage company using a developmental product from our own pipeline. In addition, it also puts us in a highly advantageous position in relation to partnering efforts for MD05. This achievement is enthusiastically shared and supported by the physician community who are highly interested in the development of a new and innovative product such as MD05.”


– ends –

About Scil Technology GmbH

Scil Technology is a privately financed biopharmaceutical development company focused on dental and orthopaedic tissue regeneration with a particular emphasis on bone and cartilage repair. The company’s therapeutic candidates are based on recombinant human growth factors.

These factors are combined with biodegradable biomaterials to generate local application forms. Scil Technology’s pipeline for dentistry includes products that are targeted at periodontal disease, dental implantology and maxillofacial surgery. Orthopaedic products are developed for treatment of traumatic lesions of bone and cartilage and osteoarthritis. Scil Technology is located in the biotechnology cluster in Martinsried, Germany. For more information please visit: www.sciltechnology.com

SOURCE: Scil Technology GmbH

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top